JAK2 and myelofibrosis: Gangat, N., Begna, K.H., Al-Kali, A. Hogan, W, Litzow, M, Pardanani, A, Tefferi, A. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor.